CA2807460A1 - Compose heterocyclique et son utilisation - Google Patents

Compose heterocyclique et son utilisation Download PDF

Info

Publication number
CA2807460A1
CA2807460A1 CA2807460A CA2807460A CA2807460A1 CA 2807460 A1 CA2807460 A1 CA 2807460A1 CA 2807460 A CA2807460 A CA 2807460A CA 2807460 A CA2807460 A CA 2807460A CA 2807460 A1 CA2807460 A1 CA 2807460A1
Authority
CA
Canada
Prior art keywords
optionally substituted
halogen atom
alkyl
ring
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2807460A
Other languages
English (en)
Other versions
CA2807460C (fr
Inventor
Masakuni Kori
Toshihiro Imaeda
Shinji Nakamura
Masashi Toyofuku
Eiji Honda
Yasutomi Asano
Osamu Ujikawa
Michiyo Mochizuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CA2807460A1 publication Critical patent/CA2807460A1/fr
Application granted granted Critical
Publication of CA2807460C publication Critical patent/CA2807460C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Composé représenté par la formule (I) : - chaque symbole dans la formule étant tel que défini dans la description, ou sel de celui-ci, ayant une action de potentialisation du récepteur AMPA (acide alpha-amino-3-hydroxy-5-méthyl- 4-isoxazolepropionique). Le composé selon la présente invention est utile à titre d'agent prophylactique ou thérapeutique pour la dépression, la schizophrénie, la maladie d'Alzheimer ou le trouble du déficit de l'attention/ hyperactivité (TDAH) et autres.
CA2807460A 2010-08-10 2011-08-09 Compose heterocyclique et son utilisation Active CA2807460C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010179577 2010-08-10
JP2010-179577 2010-08-10
PCT/JP2011/068497 WO2012020848A1 (fr) 2010-08-10 2011-08-09 Composé hétérocyclique et son utilisation

Publications (2)

Publication Number Publication Date
CA2807460A1 true CA2807460A1 (fr) 2012-02-16
CA2807460C CA2807460C (fr) 2018-09-18

Family

ID=44534564

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2807460A Active CA2807460C (fr) 2010-08-10 2011-08-09 Compose heterocyclique et son utilisation

Country Status (39)

Country Link
US (11) US8575154B2 (fr)
EP (1) EP2603513B1 (fr)
JP (2) JP5788496B2 (fr)
KR (1) KR101852215B1 (fr)
CN (2) CN103180326B (fr)
AR (1) AR082618A1 (fr)
AU (1) AU2011290126B2 (fr)
BR (1) BR112013002250B1 (fr)
CA (1) CA2807460C (fr)
CL (1) CL2013000380A1 (fr)
CO (1) CO6680700A2 (fr)
CR (1) CR20130066A (fr)
CY (1) CY1123507T1 (fr)
DK (1) DK2603513T3 (fr)
DO (1) DOP2013000030A (fr)
EA (1) EA022078B1 (fr)
EC (1) ECSP13012478A (fr)
ES (1) ES2793723T3 (fr)
GE (1) GEP20156216B (fr)
HR (1) HRP20200844T1 (fr)
HU (1) HUE049460T2 (fr)
IL (1) IL224452A (fr)
LT (1) LT2603513T (fr)
MA (1) MA34509B1 (fr)
MX (1) MX349470B (fr)
MY (1) MY165908A (fr)
NZ (1) NZ607593A (fr)
PE (1) PE20131116A1 (fr)
PH (1) PH12013500247A1 (fr)
PL (1) PL2603513T3 (fr)
PT (1) PT2603513T (fr)
RS (1) RS60311B1 (fr)
SG (1) SG187656A1 (fr)
SI (1) SI2603513T1 (fr)
TW (1) TWI504604B (fr)
UA (1) UA111594C2 (fr)
UY (1) UY33551A (fr)
WO (1) WO2012020848A1 (fr)
ZA (1) ZA201301120B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2603513T (lt) * 2010-08-10 2020-05-25 Takeda Pharmaceutical Company Limited Heterociklinis junginys ir jo panaudojimas kaip ampa receptoriaus teigiamo alosterinio moduliatoriaus
EP2694472B1 (fr) * 2011-04-05 2020-03-11 Takeda Pharmaceutical Company Limited Dérivé de sulfonamide et son utilisation
JP6134654B2 (ja) * 2012-02-08 2017-05-24 武田薬品工業株式会社 複素環化合物およびその用途
EP3008167A4 (fr) * 2013-06-13 2017-06-07 VeroScience LLC Compositions et méthodes pour le traitement des troubles métaboliques
SG11201509186TA (en) 2013-06-27 2016-01-28 Pfizer Heteroaromatic compounds and their use as dopamine d1 ligands
US11589583B2 (en) 2013-12-03 2023-02-28 Fmc Corporation Pyrrolidinones herbicides
CA2931961C (fr) 2013-12-03 2023-10-31 Andrew Duncan Satterfield Pyrrolidinones servant d'herbicides
SG11201610720VA (en) 2014-07-02 2017-01-27 Du Pont Piperidinone herbicides
CN107001260B (zh) 2014-12-08 2020-11-10 Fmc公司 3-氧基-3-(芳氨基)丙酸酯、其制备方法、以及其在制备吡咯烷酮中的用途
EP3280709B1 (fr) 2015-04-10 2021-05-26 FMC Corporation Amides cycliques susbtitués utilisés comme herbicides
BR112017020094B1 (pt) 2015-04-27 2022-01-11 Fmc Corporation Composto, composições herbicidas, mistura de herbicida e método para controlar o crescimento de vegetação indesejada
RS61688B1 (sr) 2015-04-29 2021-05-31 Janssen Pharmaceutica Nv Azabenzimidazoli i njihiova upotreba kao modulatori ampa receptora
WO2016176457A1 (fr) * 2015-04-29 2016-11-03 Janssen Pharmaceutica Nv Imidazopyrazines et pyrazolopyrimidines et leur utilisation comme modulateurs des récepteurs ampa
JP7000160B2 (ja) 2015-05-12 2022-01-19 エフ エム シー コーポレーション 除草剤としてのアリール置換二環式化合物
JP6869192B2 (ja) 2015-05-29 2021-05-12 エフ エム シー コーポレーションＦｍｃ Ｃｏｒｐｏｒａｔｉｏｎ 除草剤としての置換環状アミド
CN107709310B (zh) 2015-06-02 2021-09-24 Fmc公司 取代的环酰胺及其作为除草剂的用途
JP6937290B2 (ja) 2015-07-31 2021-09-22 エフ エム シー コーポレーションＦｍｃ Ｃｏｒｐｏｒａｔｉｏｎ 除草剤として有用な環状ｎ−カルボキサミド化合物
CA2982825C (fr) * 2015-08-06 2023-10-17 F. Hoffmann-La Roche Ag Procedes pour la preparation de derives acides de galnac
US20170181292A1 (en) * 2015-12-16 2017-06-22 Rohm And Haas Electronic Materials Llc Method for forming organic coating on nickel surface
CN105669731B (zh) * 2016-01-10 2017-06-30 沧州普瑞东方科技有限公司 一种4‑(4‑烷基环己氧基)苯硼酸的合成方法
RU2019122791A (ru) 2016-12-21 2021-01-25 Фмк Корпорейшн Гербициды на основе нитрона
CN107892697B (zh) 2016-12-26 2020-11-03 郑州泰基鸿诺医药股份有限公司 一种[1,3]噻嗪-2-胺类化合物及应用，药物组合物
MX2019010969A (es) 2017-03-21 2019-12-02 Fmc Corp Pirrolidinonas y proceso para prepararlas.
CN110740646B (zh) 2017-03-21 2022-05-10 Fmc公司 除草剂混合物、组合物和方法
AR111967A1 (es) 2017-05-30 2019-09-04 Fmc Corp Amidas herbicidas
AR111839A1 (es) 2017-05-30 2019-08-21 Fmc Corp Lactamas 3-sustituidas herbicidas
ES2970624T3 (es) 2017-10-06 2024-05-29 Takeda Pharmaceuticals Co Compuesto heterocíclico
EP3693360B1 (fr) * 2017-10-06 2023-12-13 Takeda Pharmaceutical Company Limited Composés hétérocycliques
AU2020348675B2 (en) 2019-09-16 2025-11-20 Takeda Pharmaceutical Company Limited Azole-fused pyridazin-3(2H)-one derivatives
US20230338391A1 (en) * 2020-05-15 2023-10-26 Takeda Pharmaceutical Company Limited Treatment for depression
CN113943294A (zh) * 2020-07-15 2022-01-18 成都海博为药业有限公司 一种作为btk抑制剂的化合物及其制备方法与用途
WO2025224508A1 (fr) 2024-04-22 2025-10-30 Takeda Pharmaceutical Company Limited Composition pharmaceutique pour le traitement de troubles dépressifs
WO2026050231A1 (fr) 2024-08-27 2026-03-05 Neurocrine Biosciences, Inc. Méthode de traitement d'un trouble bipolaire

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0437742Y2 (fr) 1986-10-22 1992-09-04
JPH0285851A (ja) * 1988-09-22 1990-03-27 Konica Corp 新規な写真用カプラー
JPH037742A (ja) 1989-06-05 1991-01-14 Toyo Tire & Rubber Co Ltd ラバーチエーン用ゴム組成物
JP2874960B2 (ja) * 1990-06-03 1999-03-24 コニカ株式会社 新規な染料を含有するハロゲン化銀写真感光材料
JPH04119890A (ja) * 1990-09-11 1992-04-21 Konica Corp ピラゾロチアジアジン系色素
JP3430375B2 (ja) * 1993-11-12 2003-07-28 コニカ株式会社 感熱転写材料及び該材料に好適な色素
DE19704923A1 (de) 1997-02-10 1998-08-13 Hoechst Schering Agrevo Gmbh Klebstoffhaltige Schädlingsbekämpfungsmittel
EP1229786A1 (fr) 1999-11-04 2002-08-14 Colorado State University Procede et dispositif pour attirer les insectes
FR2801587B1 (fr) 1999-11-30 2002-01-11 Adir Nouveaux derives de benzothiadiazines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2005508352A (ja) * 2001-10-10 2005-03-31 ニューロサーチ、アクティーゼルスカブ 新規ベンゾチアジン誘導体、その製造方法及びその使用方法
FR2833955B1 (fr) * 2001-12-21 2004-01-30 Servier Lab Nouveaux derives de benzothiazine et de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2854634B1 (fr) 2003-05-05 2005-07-08 Servier Lab Nouveaux derives de thiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2865474B1 (fr) 2004-01-26 2008-06-13 Servier Lab Nouveaux derives de benzothiazines fluorees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2879201B1 (fr) 2004-12-10 2007-02-16 Servier Lab Nouveaux derives de benzothiazine et benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2655376A1 (fr) 2006-06-23 2007-12-27 Nufarm Australia Limited Composition herbicide de phenoxy-alcanoate et procede de preparation et utilisation
US8097652B2 (en) 2006-12-11 2012-01-17 Eli Lilly And Company AMPA receptor potentiators
US20080167374A1 (en) 2007-01-09 2008-07-10 Loveland Products, Inc. Pesticide composition and method of use
US8487099B2 (en) * 2007-11-05 2013-07-16 Merck Sharp & Dohme Corp. Gamma secretase modulators
CA2709784A1 (fr) * 2007-12-21 2009-07-09 University Of Rochester Procede permettant de modifier la duree de vie d'organismes eucaryotes
WO2009119088A1 (fr) 2008-03-25 2009-10-01 武田薬品工業株式会社 Composé hétérocyclique
JP2009248543A (ja) * 2008-04-11 2009-10-29 Fujifilm Corp 光情報記録媒体および情報記録方法
TW201012803A (en) 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
EP2356115A1 (fr) * 2008-11-06 2011-08-17 Schering Corporation Modulateurs de sécrétase gamma
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
JP2012051806A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
FR2943342B1 (fr) 2009-03-20 2011-03-04 Servier Lab Nouveaux derives de benzothiadiazepines,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
WO2010140339A1 (fr) 2009-06-01 2010-12-09 武田薬品工業株式会社 Composé hétérocyclique
EP2455380A4 (fr) 2009-07-13 2012-11-28 Takeda Pharmaceutical Composé hétérocyclique et son utilisation
WO2011036885A1 (fr) 2009-09-25 2011-03-31 武田薬品工業株式会社 Composé hétérocyclique
WO2011036889A1 (fr) 2009-09-25 2011-03-31 武田薬品工業株式会社 Composé hétérocyclique
LT2603513T (lt) * 2010-08-10 2020-05-25 Takeda Pharmaceutical Company Limited Heterociklinis junginys ir jo panaudojimas kaip ampa receptoriaus teigiamo alosterinio moduliatoriaus

Also Published As

Publication number Publication date
MA34509B1 (fr) 2013-09-02
US8916551B2 (en) 2014-12-23
CN104926837A (zh) 2015-09-23
RS60311B1 (sr) 2020-07-31
CR20130066A (es) 2013-05-03
JP2016006080A (ja) 2016-01-14
GEP20156216B (en) 2015-01-12
CN103180326A (zh) 2013-06-26
UY33551A (es) 2012-03-30
MX349470B (es) 2017-07-31
US9150591B2 (en) 2015-10-06
CL2013000380A1 (es) 2013-05-31
US20240360156A1 (en) 2024-10-31
ES2793723T3 (es) 2020-11-16
KR20130138738A (ko) 2013-12-19
NZ607593A (en) 2015-01-30
JP5788496B2 (ja) 2015-09-30
PT2603513T (pt) 2020-06-08
MX2013001614A (es) 2013-07-05
US8778934B2 (en) 2014-07-15
SI2603513T1 (sl) 2020-07-31
UA111594C2 (uk) 2016-05-25
DOP2013000030A (es) 2013-03-15
US20140080817A1 (en) 2014-03-20
TW201217386A (en) 2012-05-01
ZA201301120B (en) 2014-04-30
AR082618A1 (es) 2012-12-19
CN103180326B (zh) 2015-06-10
AU2011290126A1 (en) 2013-03-07
JP6113789B2 (ja) 2017-04-12
AU2011290126B2 (en) 2016-01-07
CA2807460C (fr) 2018-09-18
PH12013500247A1 (en) 2013-03-11
HUE049460T2 (hu) 2020-09-28
DK2603513T3 (da) 2020-06-15
WO2012020848A8 (fr) 2012-09-27
US20180162875A1 (en) 2018-06-14
US11279713B2 (en) 2022-03-22
US10654874B2 (en) 2020-05-19
ECSP13012478A (es) 2013-04-30
MY165908A (en) 2018-05-18
EA201390222A1 (ru) 2013-08-30
LT2603513T (lt) 2020-05-25
SG187656A1 (en) 2013-03-28
EP2603513B1 (fr) 2020-03-11
JP2013535408A (ja) 2013-09-12
CO6680700A2 (es) 2013-05-31
US8575154B2 (en) 2013-11-05
US20130190291A1 (en) 2013-07-25
US20190263832A1 (en) 2019-08-29
PL2603513T3 (pl) 2020-07-27
US20150073137A1 (en) 2015-03-12
US20120077799A1 (en) 2012-03-29
US20200317692A1 (en) 2020-10-08
BR112013002250A2 (pt) 2016-05-24
US20170022222A1 (en) 2017-01-26
US9499568B2 (en) 2016-11-22
US9884875B2 (en) 2018-02-06
CY1123507T1 (el) 2022-03-24
US20130184266A1 (en) 2013-07-18
PE20131116A1 (es) 2013-10-24
EA022078B1 (ru) 2015-10-30
WO2012020848A1 (fr) 2012-02-16
HRP20200844T1 (hr) 2020-08-21
TWI504604B (zh) 2015-10-21
IL224452A (en) 2017-11-30
BR112013002250B1 (pt) 2020-10-27
US20150353578A1 (en) 2015-12-10
KR101852215B1 (ko) 2018-04-25
EP2603513A1 (fr) 2013-06-19

Similar Documents

Publication Publication Date Title
US20240360156A1 (en) Heterocyclic compound and use thereof
WO2011036889A1 (fr) Composé hétérocyclique
JP6134654B2 (ja) 複素環化合物およびその用途
HK1182701B (en) Heterocyclic compound and use thereof as ampa receptor positive allosteric modulator
HK1182701A (en) Heterocyclic compound and use thereof as ampa receptor positive allosteric modulator

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160803

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240802

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240802

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250801

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250829